UNLABELLED: The purpose of this study was to assess (18)F-FDG uptake in children with a newly diagnosed diffuse intrinsic brain stem glioma (BSG) and to investigate associations with progression-free survival (PFS), overall survival (OS), and MRI indices. METHODS: Two Pediatric Brain Tumor Consortium (PBTC) therapeutic trials in children with newly diagnosed BSG were designed to test radiation therapy combined with molecularly targeted agents (PBTC-007: phase I/II study of gefitinib; PBTC-014: phase I/II study of tipifarnib). Baseline brain (18)F-FDG PET scans were obtained in 40 children in these trials. Images were evaluated by consensus between 2 PET experts for intensity and uniformity of tracer uptake. Associations of (18)F-FDG uptake intensity and uniformity with both PFS and OS, as well as associations with tumor MRI indices at baseline (tumor volume on fluid-attenuated inversion recovery, baseline intratumoral enhancement, diffusion and perfusion values), were evaluated. RESULTS: In most of the children, BSG (18)F-FDG uptake was less than gray-matter uptake. Survival was poor, irrespective of intensity of (18)F-FDG uptake, with no association between intensity of (18)F-FDG uptake and PFS or OS. However, hyperintense (18)F-FDG uptake in the tumor, compared with gray matter, suggested poorer survival rates. Patients with (18)F-FDG uptake in 50% or more of the tumor had shorter PFS and OS than did patients with (18)F-FDG uptake in less than 50% of the tumor. There was some evidence that tumors with higher (18)F-FDG uptake were more likely to show enhancement, and when the diffusion ratio was lower, the uniformity of (18)F-FDG uptake appeared higher. CONCLUSION: Children with BSG for which (18)F-FDG uptake involves at least half the tumor appear to have poorer survival than children with uptake in less than 50% of the tumor. A larger independent study is needed to verify this hypothesis. Intense tracer uptake in the tumors, compared with gray matter, suggests decreased survival. Higher (18)F-FDG uptake within the tumor was associated with enhancement on MR images. Increased tumor cellularity as reflected by restricted MRI diffusion may be associated with increased (18)F-FDG uniformity throughout the tumor.
UNLABELLED: The purpose of this study was to assess (18)F-FDG uptake in children with a newly diagnosed diffuse intrinsic brain stem glioma (BSG) and to investigate associations with progression-free survival (PFS), overall survival (OS), and MRI indices. METHODS: Two Pediatric Brain Tumor Consortium (PBTC) therapeutic trials in children with newly diagnosed BSG were designed to test radiation therapy combined with molecularly targeted agents (PBTC-007: phase I/II study of gefitinib; PBTC-014: phase I/II study of tipifarnib). Baseline brain (18)F-FDG PET scans were obtained in 40 children in these trials. Images were evaluated by consensus between 2 PET experts for intensity and uniformity of tracer uptake. Associations of (18)F-FDG uptake intensity and uniformity with both PFS and OS, as well as associations with tumor MRI indices at baseline (tumor volume on fluid-attenuated inversion recovery, baseline intratumoral enhancement, diffusion and perfusion values), were evaluated. RESULTS: In most of the children, BSG (18)F-FDG uptake was less than gray-matter uptake. Survival was poor, irrespective of intensity of (18)F-FDG uptake, with no association between intensity of (18)F-FDG uptake and PFS or OS. However, hyperintense (18)F-FDG uptake in the tumor, compared with gray matter, suggested poorer survival rates. Patients with (18)F-FDG uptake in 50% or more of the tumor had shorter PFS and OS than did patients with (18)F-FDG uptake in less than 50% of the tumor. There was some evidence that tumors with higher (18)F-FDG uptake were more likely to show enhancement, and when the diffusion ratio was lower, the uniformity of (18)F-FDG uptake appeared higher. CONCLUSION:Children with BSG for which (18)F-FDG uptake involves at least half the tumor appear to have poorer survival than children with uptake in less than 50% of the tumor. A larger independent study is needed to verify this hypothesis. Intense tracer uptake in the tumors, compared with gray matter, suggests decreased survival. Higher (18)F-FDG uptake within the tumor was associated with enhancement on MR images. Increased tumor cellularity as reflected by restricted MRI diffusion may be associated with increased (18)F-FDG uniformity throughout the tumor.
Authors: M V Padma; S Said; M Jacobs; D R Hwang; K Dunigan; M Satter; B Christian; J Ruppert; T Bernstein; G Kraus; J C Mantil Journal: J Neurooncol Date: 2003-09 Impact factor: 4.130
Authors: C S Bruggers; H S Friedman; G N Fuller; R D Tien; L B Marks; E C Halperin; B Hockenberger; W J Oakes; J M Hoffman Journal: Med Pediatr Oncol Date: 1993
Authors: D Delbeke; C Meyerowitz; R L Lapidus; R J Maciunas; M T Jennings; P L Moots; R M Kessler Journal: Radiology Date: 1995-04 Impact factor: 11.105
Authors: G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf Journal: Neurology Date: 1982-12 Impact factor: 9.910
Authors: Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier Journal: J Nucl Med Date: 2004-08 Impact factor: 10.057
Authors: Tina Young Poussaint; Sridhar Vajapeyam; Kelsey I Ricci; Ashok Panigrahy; Mehmet Kocak; Larry E Kun; James M Boyett; Ian F Pollack; Maryam Fouladi Journal: Neuro Oncol Date: 2015-10-20 Impact factor: 12.300
Authors: Katherine A Zukotynski; Frederic H Fahey; Sridhar Vajapeyam; Sarah S Ng; Mehmet Kocak; Sridharan Gururangan; Larry E Kun; Tina Y Poussaint Journal: J Nucl Med Date: 2013-06-25 Impact factor: 10.057
Authors: Mark W Kieran; Susan Chi; Stewart Goldman; Arzu Onar-Thomas; Tina Young Poussaint; Sridhar Vajapeyam; Frederic Fahey; Shengjie Wu; David C Turner; Clinton F Stewart; Marsha Moses; Roger J Packer; Regina Jakacki; Anu Banerjee; James M Boyett; Maryam Fouladi; Larry Kun Journal: Childs Nerv Syst Date: 2015-07-19 Impact factor: 1.475
Authors: Marc H Jansen; Sophie E Veldhuijzen van Zanten; Esther Sanchez Aliaga; Martijn W Heymans; Monika Warmuth-Metz; Darren Hargrave; Erica J van der Hoeven; Corrie E Gidding; Eveline S de Bont; Omid S Eshghi; Roel Reddingius; Cacha M Peeters; Antoinette Y N Schouten-van Meeteren; Rob H J Gooskens; Bernd Granzen; Gabriel M Paardekooper; Geert O Janssens; David P Noske; Frederik Barkhof; Christof M Kramm; W Peter Vandertop; Gertjan J Kaspers; Dannis G van Vuurden Journal: Neuro Oncol Date: 2014-06-05 Impact factor: 12.300
Authors: Sean J Hipp; Emilie A Steffen-Smith; Nicholas Patronas; Peter Herscovitch; Jeffrey M Solomon; Robyn S Bent; Seth M Steinberg; Katherine E Warren Journal: J Neurooncol Date: 2012-07-04 Impact factor: 4.130
Authors: Christopher L Tinkle; Elizabeth C Duncan; Mikhail Doubrovin; Yuanyuan Han; Yimei Li; Hyun Kim; Alberto Broniscer; Scott E Snyder; Thomas E Merchant; Barry L Shulkin Journal: J Nucl Med Date: 2018-08-02 Impact factor: 10.057